tiprankstipranks
Trending News
More News >

Vaxart Resumes COVID-19 Vaccine Trial After Government Lift

Story Highlights

Protect Your Portfolio Against Market Uncertainty

Vaxart ( (VXRT) ) has shared an update.

On May 5, 2025, Vaxart, Inc. announced significant progress in its vaccine programs, including the lifting of a government stop work order on April 24, 2025, which allows the continuation of a clinical trial for its COVID-19 vaccine candidate. The company is also advancing its norovirus program and is on track to report topline data by mid-2025. Vaxart is proposing a reverse stock split to be voted on at the upcoming annual meeting to avoid Nasdaq delisting, which could impact liquidity and funding opportunities. The company is implementing cost control measures to extend its cash runway into 2026 and is actively seeking non-dilutive funding to support its strategic initiatives.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s overall score is driven by strong revenue growth and progress in its norovirus vaccine program, providing a positive outlook. However, significant challenges in profitability, cash flow management, and uncertainties in the COVID-19 program weigh heavily on the stock. Technical indicators suggest bearish momentum, while valuation metrics highlight financial struggles. The company’s strategic initiatives and cash management efforts offer some hope for future stability, but current risks remain substantial.

To see Spark’s full report on VXRT stock, click here.

More about Vaxart

Vaxart, Inc. operates in the biotechnology industry, focusing on the development of oral pill vaccines aimed at transforming global public health. The company is particularly engaged in advancing vaccine candidates for COVID-19 and norovirus, with a strategic emphasis on maintaining its listing on Nasdaq to support its ongoing research and development efforts.

YTD Price Performance: -37.47%

Average Trading Volume: 1,939,391

Technical Sentiment Signal: Buy

Current Market Cap: $102.6M

For detailed information about VXRT stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App